Endometrial cancer trials in China

In China 86 Also abroad 395

86 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
Where
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Henan, Jinan, Jining, Lanzhou, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shantou, Tianjin, Wenzhou, Wuhan, Xiamen, Xi'an, Xiangyang, Yantai, Zhengzhou
Age
18 years and over
People
480 worldwide
Run by
BioNTech SE
See details and how to joinNCT06340568 · EU 2023-507525-42-00
Phase 3Taking people
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linhai, Linyi, Liuzhou, Nanchang, Nanjing, Nanning, Shanghai, Shantou, Taiyuan, Wenzhou, Wuhan, Xiamen, Xi'an, Yibin, Zhanjiang, Zhengzhou
Age
18 years and over
People
1,123 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06952504 · EU 2024-519331-42-00
Phase 1/2Taking people
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fujian, Guangdong, Hangzhou, Henan, Hubei, Nanchang, Shanghai, Shanxi, Shengyang, Tianjin
Age
18 years and over
People
952 worldwide
Run by
Genmab
See details and how to joinNCT05579366
Phase 2Taking people
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Beijing, Changsha, Hangzhou, Shanghai
Age
18 years and over
People
111 worldwide
Run by
Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00
Phase 3Taking people
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
Where
Shanghai
Age
18 years and over
People
600 worldwide
Run by
Pfizer
See details and how to joinNCT07578649 · EU 2026-525584-40-00
Phase 1Taking people
A Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors
Where
Shanghai
Age
18 years and over
People
128
Run by
TJ Biopharma Co., Ltd.
See details and how to joinNCT07715747
Phase 3Taking people
HB0025-C-0301: A Study to Investigate HB0025 Combined With Chemotherapy as First-Line Treatment for Advanced or Recurrent MMR-proficient Endometrial Cancer
Where
Guangzhou, Shenyang
Age
18 years and over
People
333
Run by
Shanghai Huaota Biopharmaceutical Co., Ltd.
See details and how to joinNCT07902999
Phase 3Taking people
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
Where
Beijing, Changchun, Chengdu, Hangzhou, Jinan, Linyi, Nanchang, Nanning, Shanghai, Tianjin, Wenzhou, Wuhan, Yantai
Age
18 years and over
People
710 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT07022483 · EU 2024-519444-33-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Chengdu, Guangzhou
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1Taking people
A Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors
Where
Beijing
Age
18 years to 75 years
People
96
Run by
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
See details and how to joinNCT06531486
No phaseTaking people
Feasibility of the "One-Finger Technique" for Identifying the Upper Left Ureter During Para-Aortic Lymphadenectomy
Where
Guangzhou
Age
18 years to 75 years
People
40
Run by
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07895212
No phaseTaking people
Liquid Biopsy-Based Early Screening for Endometrial Cancer in Regional Chinese Populations
Where
Guiyang
Age
Up to 18 years
People
512
Run by
Guizhou Provincial People's Hospital
See details and how to joinNCT07892755
Phase 2Not yet taking people in China
Canagliflozin Plus Progestin for Atypical Endometrial Hyperplasia and Early-Stage Endometrial Cancer
Where
Tianjin
Age
18 years to 45 years
People
102
Run by
Wang Yingmei
See details and how to joinNCT07890064
Phase 2Taking people
QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer
Where
Tianjin
Age
18 years to 70 years
People
30
Run by
Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT06917092
No phaseNot yet taking people in China
Effect of Weight Management on AMPK Activation in the Adjunctive Treatment of Endometrial Cancer
Where
Beijing
Age
18 years and over
People
160
Run by
Peking University People's Hospital
See details and how to joinNCT07879365
Phase 1/2Taking people
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Where
Beijing, Changsha, Chongqing, Guangzhou, Kunming, Shandong
Age
18 years and over
People
460 worldwide
Run by
AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01
Phase 3Taking people
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Jining, Kunming, Lanzhou, Nanchang, Nanning, Shanghai, Shantou, Shenyang, Taiyuan, Tianjin, Ürümqi, Wuhan, Xi'an, Xuzhou, Yibin
Age
18 years and over
People
600 worldwide
Run by
AstraZeneca
See details and how to joinNCT06989112 · EU 2023-508056-19-00
Phase 1/2Taking people
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Where
Beijing, Fuzhou, Guangzhou, Shandong, Shanghai
Age
18 years and over
People
233 worldwide
Run by
Ensem Therapeutics
See details and how to joinNCT06993844
No phaseTaking people
Stellate Ganglion Block and Dexmedetomidine for Postoperative Sleep in Women Undergoing Laparoscopic Gynecologic Surgery
Where
Huai'an
Age
18 years to 75 years
People
100
Run by
Catherin Zhang
See details and how to joinNCT07860203
Phase 1/2Taking people
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Where
Chengdu, Chongqing, Guangzhou, Jinan, Xi'an, Zhengzhou
Age
18 years to 130 years
People
622 worldwide
Run by
AstraZeneca
See details and how to joinNCT05797168 · EU 2022-502576-23-00
Phase 2Taking people
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Where
Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Shanghai, Shenyang, Wuhan, Xi'an, Zhengzhou
Age
18 years to 130 years
People
454 worldwide
Run by
AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00
No phaseTaking people
Clinical Research on Moderately Hypofractionated Adaptive Postoperative Radiotherapy for High-Risk Endometrial Cancer
Where
Beijing
Age
18 years to 70 years
People
20
Run by
Xiaorong Hou
See details and how to joinNCT07116213
No phaseTaking people
MH-ART vs CF-IMRT in Postoperative Cervical/Endometrial Cancer
Where
Beijing
Age
18 years to 75 years
People
228
Run by
Xiaorong Hou
See details and how to joinNCT07584161
Phase 2/3Taking people
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
Where
Shanghai
Age
18 years to 45 years
People
80
Run by
Xiaojun Chen
See details and how to joinNCT05316935
Phase 2/3Taking people
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
Where
Shanghai
Age
18 years to 45 years
People
29
Run by
Xiaojun Chen
See details and how to joinNCT06379113